PATENT CLAIM ANALYSIS

Application Number: 15924250
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "381000"]

Abstract:
Novel crystalline forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.

Claim (Index 7):
The crystalline form of  claim 1  in the form of a monoclinic crystal system.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 90.0
- Lexical Diversity: 1.3871
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15528153', '15764244', '11722360', '14311788', '15568550']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7912958433062524
- 35 USC 102 Novelty (BERT): 0.6170659431881856
- Combined Prediction Score: 0.7738728532944457
- Mean Citation Score: 363.97922
- Max Citation Score: 613.86475
- Similarity Product: 485.7286003834903

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test